Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma by unknown
CLINICAL STUDY
Efficacy and safety of second-line fotemustine in elderly patients
with recurrent glioblastoma
Matteo Santoni • Silvia Scoccianti • Ivan Lolli • Maria Grazia Fabrini •
Giovanni Silvano • Beatrice Detti • Franco Perrone • Giuseppina Savio •
Roberto Iacovelli • Luciano Burattini • Rossana Berardi • Stefano Cascinu
Received: 21 December 2012 / Accepted: 23 March 2013 / Published online: 6 April 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Fotemustine (FTM) is a common treatment
option for glioblastoma patients refractory to temozolo-
mide (TMZ). Although elderly patients represent a large
component of glioblastoma population, the feasibility and
the efficacy of second-line FTM are not available in those
patients.We retrospectively analyzed the records of glio-
blastoma patients older than 65 years, receiving FTM at a
dose of 70–100 mg/m2 of FTM every week for 3 consec-
utive weeks (induction phase) and then every 3 weeks
(70–100 mg/m2), as second-line treatment.Between Janu-
ary 2004 and December 2011, 65 glioblastoma patients
(median age, 70 years; range, 65–79 years) were eligible
for this analysis. Sixty-five patients received a total of 364
FTM cycles, with a median of 4 cycles for each patient.
After induction, we observed 1 complete response (1.5 %),
12 partial responses (18.5 %), 18 stable diseases (27.7 %),
and 34 patients’ progressions (47.7 %). Disease control
rate was 43.1 %. Median survival from the beginning of
FTM therapy was 7.1 months, while the median progres-
sion-free survival was 4.2 months, and the 6-months pro-
gression free survival rate was 35.4 %. The most relevant
grade 3–4 toxicity events were thrombocytopenia (15.3 %)
and neutropenia (9.2 %). In the univariate and multivariate
analysis, time from radiotherapy to FTM, number of TMZ
and FTM cycles and disease control resulted independent
prognostic factors.This study showed that FTM is a valu-
able therapeutic option for elderly glioblastoma patients,
with a safe toxicity profile.
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Introduction
Glioblastoma multiforme (GBM) is the most common type
of adult primary central nervous system tumour, account-
ing for 50 % of gliomas [1]. While elderly patients con-
stitute a large component of the GBM population, the
optimal management of elderly patients still remains con-
troversial. In fact, no evidence-based standard of care
exists for this unique subpopulation that is often excluded
from clinical trials. Survival of elderly GBM patients is
poor, probably due to the reduced use of standard man-
agement approaches, increased toxicity of available thera-
pies, and increased presence of comorbidities in this older
patient population.
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The advantage of debulking surgery remains unknown
in this fragile cohort of patients. Elderly patients com-
monly receive temozolomide (TMZ) or radiotherapy (RT),
even if most of them are candidate for palliative approa-
ches following surgical diagnosis [2–5]. Concurrent TMZ
chemotherapy during RT improves the survival of younger
patients with GBM [6], but the benefit in elderly patients is
unclear, although a growing body of evidence suggests that
fit elderly patients benefit from the addition of TMZ to
standard surgery and radiation [7–12].
Even more debatable is the role of a second-line che-
motherapy. Fotemustine (FTM), a third generation chlo-
roethylnitrosourea, has been investigated in malignant
glioma patients recurring after TMZ standard treatment
[13–17]. However, in these trials data on the efficacy and
feasibility in elderly patients are not available.
We retrospectively evaluated the efficacy and toxicity of
second-line FTM in elderly patients with recurrent GBM
treated with prior radiotherapy and TMZ, as well as spe-
cific independent predictors of survival.
Methods
Seven Italian centers were involved in this retrospective
analysis. Patients older than 65 years with recurrent or
progressive, histologically-confirmed GBM, previously
treated with surgery and RT plus concomitant and adjuvant
TMZ, were included in the analysis. They received 1 h
intravenous infusion of FTM according to the following
schedule: induction phase dose of 70–100 mg/m2 on days
1, 8, 15, followed by a 4/5-week rest period, and a main-
tenance phase dose of 70–100 mg/m2 every 21 days.
Toxicity was graded according to the National Cancer
Institute (NCI) common toxicity criteria (CTC, version
3.0).
Baseline MRI or CT neuro-imaging was performed
before administration of FTM, and subsequent evaluations
were carried out after completion of the induction phase,
every two cycles during the maintenance phase, according
to Macdonald’s criteria [18]. Steroid dosing was consid-
ered during radiographic disease assessment. In the pres-
ence of complete or partial responses (CR and PR) or stable
disease (SD), the time to progression (TTP) was evaluated
until progressive disease (PD), even if the treatment was
discontinued. Disease control (DC) was defined as
CR ? PR ? SD. Overall survival (OS) was measured
from the start of FTM to death for any reason, or last
follow-up assessment. Neurological status was assessed by
considering signs and symptoms possibly correlated with
progression, as compared with the previous examination.
The endpoints of this analysis were: toxicity profile, DC,
progression-free survival rate at 6 months (PFS-6) and at
1 year (PFS-1y), OS from the diagnosis and from the
beginning of FTMS, overall survival rate at 1 year (OS-1y)
and TTP.
Cox proportional hazards models were applied to
explore patients’ characteristics predictors of survival in
univariate- and multivariable-adjusted analysis using a
stepwise selection approach with type I error of 0.05 for
model entry and 0.10 for elimination. Additional elimina-
tion was applied to identify significant variables at the level
of P \ 0.05. We used PASW (Predictive Analytics Soft-
Ware) (v 18; IBM SPSS).
Results
Between January 2004 and December 2011, among the 206
GBM patients receiving FTM as second-line treatment
after surgery and concomitant radio-chemotherapy plus
adjuvant TMZ failure, 65 patients (35 males and 30
females) older than 65 years, were included in this analy-
sis. The majority of them had Karnofsky Performance
Status (KPS) >70. The demographic and clinical charac-
teristics of patients are outlined in Table 1.
All patients received at least one dose of FTM. Forty-
one patients (63.1 %) started maintenance chemotherapy,
with a median of 4 cycles received after the induction
phase (range 1–17). Eight patients (12.3 %) did not start
maintenance therapy because of a disease progression.















Gross total resection 53
Partial resection or biopsy 12
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One complete response (1.5 %), 12 partial responses
(18.5, 95 % CI: 9.1–27.9 %), 18 stable disease (27.7, 95 %
CI: 16.8–38.6 %), and 34 patients’ progressions (52.3,
95 % CI: 35.6–59.8 %) were obtained after FTM induc-
tion. Median duration of disease stabilization was
7.3 months (95 % CI: 4.5–10.1). DC was registered in
43.1 % of patients.
The median OS from the start of FTM treatment was
7.1 months (95 % CI, 1.6–35.9) and the 1y-OS rate was
20.0 % (95 % CI 10.3–29.7 %).
The median TTP for FTM was 4.2 months (95 % CI
1.2–24.1 months) (Fig. 1), with a PFS-6 rate of 35.4 %
(95 % CI 23.8–47.0 %) and PFS-1y of 13.8 % (95 % CI
5.4–22.8 %). Results are summarized in Table 2.
Fourteen patients (21.5 %) with progressive disease
after FTM and acceptable general conditions underwent a
third line chemotherapy.
All 65 patients exposed to FTM were evaluated for safety.
FTM administration was well tolerated and the most relevant
grade 3–4 toxicity events were thrombocytopenia (15.3 %)
and neutropenia (9.2 %) (Table 3). Only one patient, with
prolonged grade 2 thrombocytopenia, discontinued therapy
due to toxicity during the induction phase. None of the
patients manifested constitutional or neurological symptoms
during FTM treatment. No significant differences in terms of
incidence of hematologic toxicities were found in patients
stratified by age (>65/>70/>75).
Furthermore, we performed an univariate and multi-
variate analysis to evaluate the impact of gender, time from
RT to FTM, number of TMZ and FTM cycles and DC on
OS and PFS of elderly patients. In univariate analysis, time
from RT to FTM (P \ 0.001), number of TMZ
(P = 0.001) and FTM cycles (P \ 0.001) and DC
(P \ 0.001) had a significant impact on OS, whereas only
time from RT to FTM and number of TMZ cycles signif-
icantly affected PFS. Multivariate analysis showed time
from RT to FTM (P \ 0.001), number of TMZ
(P \ 0.001) and FTM cycles (P \ 0.001) and DC
(P = 0.021) for OS and time from RT to FTM (P = 0.03)
and number of TMZ cycles (P \ 0.001) for PFS as inde-
pendent prognostic factors (Tables 4, 5).
Discussion
Recurrent GBM is resistant to most therapeutic approaches
and elderly patients ([65 years old) have a significantly
worse life expectancy compared with younger patients. In
Fig. 1 Overall survival (OS), survival after fotemustine and progres-
sion-free survival (PFS) in elderly glioblastoma patients treated with
fotemustine as second-line therapy
Table 2 Results obtained by using fotemustine as second-line ther-
apy in elderly patients with recurrent glioblastoma
Objective responses
Complete responses (CR) 1 (1.5 %)
Partial responses (PR) 12
(18.5 %)
Stable diseases (SD) 18
(27.7 %)
Progressive diseases (PD) 34
(52.3 %)
Disease control (DC) 43.1 %
Median overall survival (months) 20.6
Median overall survival from II line fotemustine
(months)
7.1
Progression free survival (months) 4.2
Six months-progression free survival (%) 35.4 %
One year-progression free survival (%) 13.8 %
Table 3 Incidence of drug-related adverse events during II line
treatment with fotemustine in elderly patients with recurrent
glioblastoma
Thrombocytopenia N (%)
Grade 1–2 9 (13.8)
Grade 3–4 10 (15.3)
Leukopenia
Grade 1–2 11 (16.9)
Grade 3–4 6 (9.2)
Neutropenia
Grade 1–2 7 (10.8)
Grade 3–4 6 (9.2)
Lymphopenia
Grade 1–2 6 (10.0)
Grade 3–4 5 (7.7)
Anemia
Grade 1–2 4 (6.2)
Grade 3–4 2 (3.1)
Transaminase elevation
Grade 1–2 5 (7.7)
Grade 3–4 3 (4.6)
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addition, no evidence-based standard of care exists for this
unique subpopulation (Table 6).
Elderly patients with GBM represent a major focus in
neuro-oncology. Recently, Malmstro¨m et al. have led a phase
III study of GBM patients older then 60y, randomized to
receive TMZ vs. standard 6-week radiotherapy versus hypo-
fractionated radiotherapy. The results showed that standard
radiotherapy was associated with poor outcomes, suggesting
to consider both TMZ and hypofractionated radiotherapy as
standard treatment options in elderly patients with GBM [19].
Additionally, Wick et al. has recently reported that TMZ alone
is non-inferior to radiotherapy alone in the treatment of elderly
patients with malignant astrocytoma [20].
FTM has been demonstrated to represent a valid option
for patients with recurrent or progressive GBM. Several
trials [13–17] have investigated the use of FTM in
recurrent GBM patients, with the PFS-6 ranging from the
20 % reported by GICNO [14] to the 48 and 51.5 %
reported, respectively by Scoccianti et al. [15] and Fabrini
et al. [16] (Table 6). In these studies, myelosuppression
was the most common adverse event that occurred, mainly
during the induction phase of treatment and more fre-
quently in TMZ pretreated patients.
The comparison between the results reported by Pac-
capelo [17] and Perry [21] could suggest a potentially
different response pattern between recurrent GBM patients
treated with FTM and those with rechallenge TMZ. Indeed,
TMZ seemed to be active in early and late progression
patients, while FTM was always active in recurrent
patients. The major difference was registered in GBM
patients who failed after more than 6 months of TMZ [17].
Our retrospective study represents the first report on effi-
cacy and safety of FTM in elderly patients with recurrent
GBM. In our analysis, FTM was a valuable therapeutic option
for elderly patients with recurrent GBM, obtaining a median
OS of 7.1 months, a PFS-6 of 35.4 % and a median PFS of
4.2 months. In addition, FTM administration was feasible
with an acceptable toxicity, even in this group of patients.
When stratified by age category ([65/[70/[75), no
significant differences were registered in the incidence of
hematologic adverse events, although this analysis is lim-
ited by the small number of patients [75y in our study.
Furthermore, in our study population, time from RT to
FTM, number of TMZ and FTM cycles and DC resulted
independent treatment-related prognostic factors. It is also
Table 4 Univariate and multivariate analysis of OS in elderly patients treated with fotemustine for recurrent glioblastoma
OS Univariate Cox regression Multivariable Cox regression
HR (95 %CI) p value HR (95 %CI) p value
Sex (m/f) 1.07 (0.63–1.80) 0.809
N cycles of TMZ (cont) 0.89 (0.84–0.95) 0.001 0.77 (0.68–0.88) \0.001
Time from RT to FTM 0.89 (0.84–0.93) \0.001 0.90 (0.85–0.95) \0.001
N cycles of FTMS (cont) 0.35 (0.20–0.61) \0.001 0.84 (0.78–0.91) \0.001
Disease control (n/y) 2.72 (1.56–4.75) \0.001 2.03 (1.11–3.69) 0.021
OS overall survival, HR hazard ratio, CI confidence interval, TMZ temozolomide, FTM fotemustine, N number, cont continuous variable, RT
radiotherapy
Table 5 Univariate and multivariate analysis of PFS in elderly patients treated with fotemustine for recurrent glioblastoma
PFS Univariate Cox regression Multivariable Cox regression
HR (95 %CI) p Value HR (95 %CI) p value
Sex (m/f) 1.29 (0.79–2.11) 0.311
Time from RT to FTM 0.95 (0.92–0.99) 0.008 0.95 (0.91–0.99) 0.03
N cycles of TMZ (cont) 0.87 (0.81–0.93) \0.001 0.87 (0.81–0.93) \0.001
OS overall survival, HR hazard ratio, CI confidence interval, TMZ temozolomide, FTM fotemustine, N number, cont continuous variable, RT
radiotherapy







Malhaire et al. [13] 1999 22 6.5 NR
Scoccianti et al. [15] 2008 27 5.7 48.2
Brandes et al. [7] 2009 43 NR 20.9
Fabrini et al. [16] 2009 50 6.1 51.5
Paccapelo et al. [17] 2012 163 NR 25.0–43.8
OS overall survival, PFS progression-free survival, PFS-6 progres-
sion-free survival at 6 months, NR not reported
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of interest the high percentage (21.5 %) of patients still fit
for third line chemotherapy after FTM failure.
However, elderly GBM patients fit for second-line
therapies are good prognosis patients, and our data in terms
of tolerance and efficacy of FTM may not be extended to
the overall elderly GBM population.
In conclusion, FTM may be considered as a treatment
option, even for elderly GBM patients, especially for those
receiving a significant benefit from prior TMZ therapy and
with good KPS. Based on these data these patients should
definitely be included in adult patients clinical trials.
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